These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 22552994)

  • 21. Complications of biologics in inflammatory bowel disease.
    Sousa P; Allez M
    Curr Opin Gastroenterol; 2015 Jul; 31(4):296-302. PubMed ID: 26039721
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Anti-TNF agents in patients with inflammatory bowel disease and malignant melanoma--challenges in management.
    Lee J; Clarke K
    Int J Colorectal Dis; 2015 Dec; 30(12):1595-602. PubMed ID: 26349591
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The Relevance of Vitamin D and Antinuclear Antibodies in Patients with Inflammatory Bowel Disease Under Anti-TNF Treatment: A Prospective Study.
    Santos-Antunes J; Nunes AC; Lopes S; Macedo G
    Inflamm Bowel Dis; 2016 May; 22(5):1101-6. PubMed ID: 26818421
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The Influence of Anti-tumor Necrosis Factor Agents on Hemoglobin Levels of Patients with Inflammatory Bowel Disease.
    Koutroubakis IE; Ramos-Rivers C; Regueiro M; Koutroumpakis E; Click B; Schwartz M; Swoger J; Baidoo L; Hashash JG; Barrie A; Dunn MA; Binion DG
    Inflamm Bowel Dis; 2015 Jul; 21(7):1587-93. PubMed ID: 25933393
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Extraintestinal considerations in inflammatory bowel disease.
    Levine JB; Lukawski-Trubish D
    Gastroenterol Clin North Am; 1995 Sep; 24(3):633-46. PubMed ID: 8809240
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Immune-mediated inflammatory reactions and tumors as skin side effects of inflammatory bowel disease therapy.
    Marzano AV; Borghi A; Meroni PL; Crosti C; Cugno M
    Autoimmunity; 2014 May; 47(3):146-53. PubMed ID: 24437626
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Psoriasiform Skin Lesions Are Caused by Anti-TNF Agents Used for the Treatment of Inflammatory Bowel Disease.
    George LA; Gadani A; Cross RK; Jambaulikar G; Ghazi LJ
    Dig Dis Sci; 2015 Nov; 60(11):3424-30. PubMed ID: 26115749
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Anti-TNF alpha therapy in the management of extraintestinal manifestation of inflammatory bowel disease.
    Andrisani G; Guidi L; Papa A; Armuzzi A
    Eur Rev Med Pharmacol Sci; 2012 Jul; 16(7):890-901. PubMed ID: 22953637
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Neurologic manifestations in inflammatory bowel diseases: current knowledge and novel insights.
    Zois CD; Katsanos KH; Kosmidou M; Tsianos EV
    J Crohns Colitis; 2010 Jun; 4(2):115-24. PubMed ID: 21122494
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cutaneous manifestations in inflammatory bowel diseases: eight cases of psoriasis induced by anti-tumor-necrosis-factor antibody therapy.
    Passarini B; Infusino SD; Barbieri E; Varotti E; Gionchetti P; Rizzello F; Morselli C; Tambasco R; Campieri M
    Dermatology; 2007; 215(4):295-300. PubMed ID: 17911986
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Emerging biologics in inflammatory bowel disease.
    Chan HC; Ng SC
    J Gastroenterol; 2017 Feb; 52(2):141-150. PubMed ID: 27832357
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Depressive Symptoms Predict Anti-tumor Necrosis Factor Therapy Noncompliance in Patients with Inflammatory Bowel Disease.
    Calloway A; Dalal R; Beaulieu DB; Duley C; Annis K; Gaines L; Slaughter C; Schwartz DA; Horst S
    Dig Dis Sci; 2017 Dec; 62(12):3563-3567. PubMed ID: 29052816
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Early years of biological agents therapy in Crohn's disease and risk of the human polyomavirus JC reactivation.
    Bellizzi A; Barucca V; Fioriti D; Colosimo MT; Mischitelli M; Anzivino E; Chiarini F; Pietropaolo V
    J Cell Physiol; 2010 Aug; 224(2):316-26. PubMed ID: 20432445
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The safety and efficacy of antitumour necrosis factor-alpha therapy for inflammatory bowel disease in patients post liver transplantation: a case series.
    Sandhu A; Alameel T; Dale CH; Levstik M; Chande N
    Aliment Pharmacol Ther; 2012 Jul; 36(2):159-65. PubMed ID: 22616981
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Biological treatments in pediatric IBD].
    Svensson M; Lindberg E; Ludvigsson JF
    Lakartidningen; 2017 Feb; 114():. PubMed ID: 28245034
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Safety of anti-TNF therapy in inflammatory bowel disease during pregnancy.
    Khan N; Asim H; Lichtenstein GR
    Expert Opin Drug Saf; 2014 Dec; 13(12):1699-708. PubMed ID: 25406728
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Review article: chronic viral infection in the anti-tumour necrosis factor therapy era in inflammatory bowel disease.
    Shale MJ; Seow CH; Coffin CS; Kaplan GG; Panaccione R; Ghosh S
    Aliment Pharmacol Ther; 2010 Jan; 31(1):20-34. PubMed ID: 19681818
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Pretreatment 25-hydroxyvitamin D levels and durability of anti-tumor necrosis factor-α therapy in inflammatory bowel diseases.
    Zator ZA; Cantu SM; Konijeti GG; Nguyen DD; Sauk J; Yajnik V; Ananthakrishnan AN
    JPEN J Parenter Enteral Nutr; 2014; 38(3):385-91. PubMed ID: 24088707
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Psoriasis and Psoriasiform Eruptions in Pediatric Patients with Inflammatory Bowel Disease Treated with Anti-Tumor Necrosis Factor Alpha Agents.
    Eickstaedt JB; Killpack L; Tung J; Davis D; Hand JL; Tollefson MM
    Pediatr Dermatol; 2017 May; 34(3):253-260. PubMed ID: 28211161
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Role of thiopurine and anti-TNF therapy in lymphoma in inflammatory bowel disease.
    Herrinton LJ; Liu L; Weng X; Lewis JD; Hutfless S; Allison JE
    Am J Gastroenterol; 2011 Dec; 106(12):2146-53. PubMed ID: 22031357
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.